Home / Piperacillin and Beta-Lactamase Inhibitor / United States
US ATC J01CR05 · updated 2 Nov 2026
Piperacillin and Beta-Lactamase Inhibitor shortage in United States
Is there a Piperacillin and Beta-Lactamase Inhibitor shortage in United States?
Yes. As of 2 Nov 2026, 1 Piperacillin and Beta-Lactamase Inhibitor product is reported short in United States, the first since 20 Jan 2026. No return date has been given. Main reason: not stated.
Also short in Canada, Italy, Belgium, Switzerland, Czechia, Sweden, Japan. All countries.
Affected products in United States
| Country | Product | Company | Since | Expected back | Reason |
|---|---|---|---|---|---|
| US | Piperacillin and Tazobactam, Injection, 2.25 g vial (NDC 65219-434-20) discontinuation | Fresenius Kabi USA, LLC | 20 Jan 2026 | not given | Not stated |
Source
U.S. Food and Drug Administration (FDA), Drug Shortages via openFDA. Official list. Shortages the FDA lists as current, plus products to be discontinued; one row per package (NDC).